CompletedPhase 1ACTRN12608000603314
An Open-Label, Dose Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery
Sponsor
Icon Bioscience
Enrollment
10 participants
Start Date
May 11, 2007
Study Type
Interventional
Conditions
Summary
The purpose of this study is to test the safety and tolerability of a extended duration drug delivery system for the eye.
Eligibility
Sex: Both males and femalesMin Age: 45 Yearss
Inclusion Criteria1
- Cystoid Macular Edema associated with retinal vein occlusion or post cataract surgery
Exclusion Criteria1
- Visual acuity not likely to be improved by treatment; recent treatment by other intravitreal therapies or laser therapy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravitreal injection of extended release triamcinolone acetonide for treatment of macular edema. Each patient will receive only one injection. The first cohort of five patients will all receive th
Intravitreal injection of extended release triamcinolone acetonide for treatment of macular edema. Each patient will receive only one injection. The first cohort of five patients will all receive the 6.9 mg injection. The second cohort of five patients will receive the 13.8 mg injection.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000603314